Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • MSA
    • Parkinson’s Disease
    • Posters & Publications
  • Clinical Trials
  • News & Media
    • Press Releases
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: PMN
    • Analyst Coverage
  • SEDAR
  • SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 08, 2023 5:06pm EST

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

Mar 08, 2023 7:00am EST

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022 7:00am EST

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Oct 12, 2022 7:00am EDT

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

Sep 13, 2022 7:00am EDT

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

Aug 15, 2022 5:00pm EDT

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

Aug 02, 2022 7:00am EDT

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

Jul 27, 2022 7:00am EDT

ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference

Jul 08, 2022 7:00am EDT

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

Jun 27, 2022 7:00am EDT

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …24
  • arrow_forward
  • Email Alerts
  • Contacts
Facebook Linkedin Spotify Twitter
©2025 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy